Skip to main content
CTNM logo

CTNM · Contineum Therapeutics, Inc. · Documents

Track CTNM — free
$8.68 -0.36 (-3.98%) At close · Nov 20
Market Cap
$340.83M
Shares
39.27M
Volume · Nov 20 369.22K Avg daily vol (3M) 769.71K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $59.98M 10-K filed Mar 5, 2026 Quarterly report FY2026 Q3 Net loss $18.7M 10-Q filed Nov 3, 2026 Latest results Cash runway projected through mid-2029 as trial expands 8-K filed Nov 3, 2026
2026
Nov 12
Investor event
Propel IPF completion targeted in 2028; cash runway into 2029

Continuum Therapeutics is enrolling the global phase two Propel IPF study of about 324 patients, targeting completion in 2028. About $245 million funds operations into 2029; Pipe 307 missed its MDD primary endpoint, and J&J is evaluating next steps.

8 source passages
Carmine Stegnone, President and CEO of Continuum Therapeutics. It's anticipated to enroll about 324 patients, so 108 patients per arm. And the goal for this study is to have completion in the middle of 2028. So we're about $245 million. That gives us funding all the way through the middle of 2029 we partnered with J&J in 2023 for our M1 receptor antagonist, Pipe 307. This was focused on MDD. Unfortunately, we missed on the primary endpoint. I think that they are evaluating it very carefully, and hopefully we will be able to provide more information in the near future. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
PIPE-307 trial misses efficacy endpoint as PROPEL-IPF advances

PIPE-307/JNJ-89495120 did not achieve its primary efficacy endpoint in the September 2026 MOONLIGHT-1 trial, while PROPEL-IPF dosing began in the first quarter of 2026. The Company reported $244.5 million in cash, cash equivalents and marketable securities at September 30, 2026.

Net loss $18.7M Diluted EPS -$0.49
Read from the MD&A section
4 source passages
J&J completed enrollment of 105 adult participants for its Phase 2 Moonlight-1 trial of PIPE-307, renamed by J&J to JNJ-89495120, in June 2026. In September 2026, we announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The Company initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial evaluating PIPE-791 for the treatment of patients with IPF, in the first quarter of 2026. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $244.5 million. Open the document at this passage
Nov 3
Current report 8-K
Cash runway projected through mid-2029 as trial expands

Contineum Therapeutics said the PROPEL-IPF trial of PIPE-791 had over 100 sites online in 16 countries, while $244.5 million in cash, cash equivalents and marketable securities was projected to fund operations through mid-2029.

Financial results
3 source passages
We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients. Cash, cash equivalents and marketable securities were $244.5 million as of September 30, 2026. Contineum believes its cash resources are sufficient to fund its planned operations through mid-2029. Open the document at this passage
Sep 14
Current report 8-K
Other events AI summary on its way
Apr 30
Proxy statement DEF 14A Meeting Jun 26, 2026
Proxy statement AI summary on its way
Mar 5
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $59.98M Diluted EPS -$2.17
2025
2024
Showing 1–50 of 53 documents
Key facts CIK 1855175 CUSIP 21217B100 13F (30d) 120 filings 113 filers Visit website Investor relations